[Opportunistic infections in AIDS: the benefits of an "umbrella strategy." From an interview with Professor Willy Rozenbaum].
Availability to practitioners of a treatment for infections by atypical mycobacteria by Ansatipine should produce a reduction or delay in the frequency of opportunistic infections in AIDS, which are a heavy burden on the future of the patients and seriously after their quality of life. Today, the practice of prescribing Ansatipine increase the prophylactic strategy for opportunistic infections in AIDS, or the "Umbrella strategy". This can only improve the possible therapies for practitioners who are faced with the complexity of the disease and bring real benefit to the patients. Distribution of Ansatipine to town pharmacies is a new step in this direction.
Service des Maladies Infectieuses, Hôpital Rothschild, Pris.
W
W
Rozenbaum
D017088:AIDS-Related Opportunistic Infections / Q000382:microbiology / Q000469:parasitology / Q000517:prevention & control*; D006801:Humans; D010594:Pharmacies; D011788:Quality of Life; D017828:Rifabutin / Q000600:supply & distribution / Q000627:therapeutic use*
D017828:Rifabutin
Infections opportunistes du SIDA: les bénéfices de la "stratégie du parapluie". D'après une interview du Pr WIlly ROzenbaum.